{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-000813","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.373023+00:00","generated_at":"2026-06-19T17:08:16.926703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aethlon Medical reports Q3 net loss of $2.85M; cash $17.5M; hires Lee Arnold as CSO","bullets":["Net loss increased to ~$2.85M for quarter vs $2.53M year ago; operating expenses rose 12% to $2.85M.","Cash balance ~$17.5M at Dec 31, 2022; raised $8.9M net via ATM equity offers in nine fiscal months.","Hired Lee Arnold, PhD (inventor of Tarceva) as Chief Scientific Officer; contracted NAMSA for planned oncology Hemopurifier trial.","COVID-19 ICU trial in India continues (one patient treated); preclinical mPox and Long COVID studies underway.","No government contract revenue recorded; $574K deferred revenue expected after NCI closeout review."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-000813","json":"https://secwatch.observer/filing/0001683168-23-000813.json","markdown":"https://secwatch.observer/filing/0001683168-23-000813.md","text":"https://secwatch.observer/filing/0001683168-23-000813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/0001683168-23-000813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:08:16.926703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70c30553a917b698861e230c542fdff47d55ca76","claim":"AETHLON MEDICAL INC reported third quarter ended December 31, 2022 results: net income approximately $2,850,000.","evidence_excerpt":"Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316823000813/0001683168-23-000813-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended December 31, 2022"},{"label":"Net income","value":"approximately $2,850,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}